Business
GoodRx Holdings, Inc.: The majority of the utilization of our platform relates to generic medications.
Revenue increased 0.6% to $796.9M, while Net income increased 85.7% to $30.4M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $796.9MOK
- Profitability — Net income $30.4MOK
- Cash generation — Free cash flow $164.4MOK
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — share repurchases were $216.4MNote
Where the revenue comes from
Fiscal 2025, as GoodRx Holdings, Inc. reports it. History and quarterly detail are in the app.
- Prescription transactions revenue$544.0M
- Pharma manufacturer solutions revenue$151.4M
- Subscription revenue$83.8M
- Other revenue$17.7M
Leadership changes
From GoodRx Holdings, Inc.'s own filings, the day they're filed.
- Thomas Chan · Chief Accounting Officer · appointmenteff. 2026-04-23
- Romin Nabiey · Chief Accounting Officer · departureeff. 2026-04-03
- Ian T. Clark · Directors · departureeff. 2026-03-31
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-18
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about GoodRx Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.